Clinical research in cardiology : official journal of the German Cardiac Society · 2026
Long-term LDL-C lowering and treatment persistence with inclisiran: 3-year follow-up from the German Inclisiran Network.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Makhmudova Umidakhon, Schatz Ulrike, Stuerzebecher Paulina, Schumann Friederike, Kästner Uta, Mensch Juliane, Geiling Jens Arndt, Haertel Franz, Stach Ksenija, Vogt Anja, Bässler Andrea, Sinning David, Kassner Ursula, Steinhagen-Thiessen Elisabeth, Schulze P Christian, Landmesser Ulf, Laufs Ulrich, Weingärtner Oliver
Аннотация
BACKGROUND: Inclisiran, a small interfering RNA targeting PCSK9, has demonstrated durable LDL-C lowering in clinical trials. However, real-world evidence on its long-term effectiveness and treatment persistence remains limited.
AIM: To evaluate LDL-C reductions, treatment persistence, and reasons for therapy discontinuation over a follow-up period of up to 3 years in a real-world lipid clinic cohort.
METHODS: We analyzed data from ten lipid clinics participating in the German Inclisiran Network (GIN). Adults with at least one inclisiran dose and follow-up lipid measurements were included. LDL-C levels were assessed during 3 years of follow-up (median 33 months, IQR 27-39). Discontinuation rates, therapy changes, and adverse effects were documented.
RESULTS: Among 109 patients (mean age 63.8 years, 43.1% female). The cohort comprised a heterogeneous population, with only ~ 30% receiving statins due to statin intolerance. Median (95% CI) LDL-C reduction from baseline to nadir was - 46% (- 60.8 to - 33.8%). Median for LDL-C reduction for each individual during the follow-up was - 28% (- 33.8 to - 24.2%). High interindividual and intraindividual variability in LDL-C response was observed. Over 3 years, ~ 30% of patients discontinued inclisiran, most commonly due to lack of efficacy (15.6%), adverse effects (7.3%), or a combination of both (1.8%). Those who discontinued due to lack of efficacy were older and had less background lipid-lowering therapy. Females were more likely than males to discontinue due to adverse effects. In a multivariable logistic regression model, older age was a predictor of higher discontinuation rates, whereas concomitant LLT use was associated with lower discontinuation rates. Notably, ~ 87% of patients with statin intolerance did not exhibit any adverse effects with inclisiran.
CONCLUSIONS: In a heterogeneous real-world population, inclisiran achieved significant LDL-C reductions but with marked inter- and intraindividual variability. A notable proportion of patients discontinued therapy, highlighting the importance of individualized treatment strategies.
AIM: To evaluate LDL-C reductions, treatment persistence, and reasons for therapy discontinuation over a follow-up period of up to 3 years in a real-world lipid clinic cohort.
METHODS: We analyzed data from ten lipid clinics participating in the German Inclisiran Network (GIN). Adults with at least one inclisiran dose and follow-up lipid measurements were included. LDL-C levels were assessed during 3 years of follow-up (median 33 months, IQR 27-39). Discontinuation rates, therapy changes, and adverse effects were documented.
RESULTS: Among 109 patients (mean age 63.8 years, 43.1% female). The cohort comprised a heterogeneous population, with only ~ 30% receiving statins due to statin intolerance. Median (95% CI) LDL-C reduction from baseline to nadir was - 46% (- 60.8 to - 33.8%). Median for LDL-C reduction for each individual during the follow-up was - 28% (- 33.8 to - 24.2%). High interindividual and intraindividual variability in LDL-C response was observed. Over 3 years, ~ 30% of patients discontinued inclisiran, most commonly due to lack of efficacy (15.6%), adverse effects (7.3%), or a combination of both (1.8%). Those who discontinued due to lack of efficacy were older and had less background lipid-lowering therapy. Females were more likely than males to discontinue due to adverse effects. In a multivariable logistic regression model, older age was a predictor of higher discontinuation rates, whereas concomitant LLT use was associated with lower discontinuation rates. Notably, ~ 87% of patients with statin intolerance did not exhibit any adverse effects with inclisiran.
CONCLUSIONS: In a heterogeneous real-world population, inclisiran achieved significant LDL-C reductions but with marked inter- and intraindividual variability. A notable proportion of patients discontinued therapy, highlighting the importance of individualized treatment strategies.